Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

NCT01238991 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

BIOLOGICAL: ACC-001
BIOLOGICAL: ACC-001
BIOLOGICAL: ACC-001

Sponsor

Pfizer

Collaborators

[object Object]